NASDAQ$GILD
Gilead Sciences Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Gilead Sciences reported strong Q4 2024 results with total revenue increasing by 6% year-over-year to $7.6 billion, driven by growth in HIV, Oncology, and Liver Disease product sales. EPS increased to $1.42 from $1.14 in Q4 2023, and non-GAAP EPS rose to $1.90. Operating income grew to $2.45 billion, supported by higher product sales and lower costs. Cash and cash equivalents stood at $10.0 billion as of December 31, 2024.
Headline financials
Revenue & EPS history
Gilead Sciences · Revenue · Quarterly
$7.57B
Revenue by segment
Gilead Sciences · $6.14B total across 3 segments · Q3 2023
- HIV$4.67B+4.0%76.0%
- Oncology$769M+327.2%12.5%
- Liver Disease$706M—11.5%
Forward guidance
Gilead expects stable revenue growth in 2025, with projected product sales between $28.2 billion and $28.6 billion. The company anticipates non-GAAP EPS in the range of $7.70 to $8.10, supported by strong HIV and Oncology demand.
Tailwinds
- Continued strong demand for HIV and Oncology products
- Expansion in Liver Disease portfolio with new product launches
- Improved operational efficiencies driving margin growth
- Strong cash flow supporting dividend and stock repurchases
- Potential launch of lenacapavir for HIV PrEP in Summer 2025
Headwinds
- Declining Veklury sales due to lower COVID-19 hospitalizations
- Higher operating expenses driven by litigation accruals and marketing costs
- Unrealized losses on equity investments impacting bottom line
- Increased R&D expenses due to new clinical trials and acquisitions
- Regulatory and pricing pressures in key markets
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
+0.2%
Avg return
Earnings day
-0.2%
Avg return
5 days after
-0.4%
Avg return
30 days after
44%
32 / 73 earnings
Positive
+11.9%
Q3 2022
Best reaction
-12.4%
Q1 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.5% | -1.5% | -3.4% | |
| Q4 2025 | +5.8% | +5.3% | -1.5% | |
| Q3 2025 | +3.1% | +3.5% | +6.2% | |
| Q2 2025 | +8.3% | +8.9% | +4.3% | |
| Q1 2025 | -2.8% | +0.4% | +1.1% | |
| Q4 2024 | +7.5% | +8.3% | +15.9% | |
| Q3 2024 | +8.5% | +7.5% | +2.1% | |
| Q2 2024 | -0.5% | -0.0% | +6.4% | |
| Q1 2024 | -2.5% | -2.8% | -2.1% | |
| Q4 2023 | -3.0% | -4.0% | -4.0% | |
| Q3 2023 | -4.0% | -6.4% | -3.8% | |
| Q2 2023 | +4.0% | +5.8% | +1.3% | |
| Q1 2023 | -1.8% | -3.9% | -7.9% | |
| Q4 2022 | +0.6% | +2.4% | -3.5% | |
| Q3 2022 | +11.9% | +12.0% | +21.8% | |
| Q2 2022 | +4.5% | +2.5% | +9.0% | |
| Q1 2022 | -3.7% | -2.0% | +5.2% | |
| Q4 2021 | -4.2% | -7.0% | -10.1% | |
| Q3 2021 | -2.8% | -1.3% | +5.2% | |
| Q2 2021 | -2.5% | -0.3% | +1.7% | |
| Q1 2021 | -1.5% | +1.9% | +2.6% | |
| Q4 2020 | +6.1% | +4.3% | +0.2% | |
| Q3 2020 | -2.5% | -2.5% | +0.0% | |
| Q2 2020 | -4.8% | -2.9% | -10.6% | |
| Q1 2020 | -3.8% | -4.8% | -6.4% | |
| Q4 2019 | -0.7% | +3.8% | +14.7% | |
| Q3 2019 | -4.9% | -4.7% | -2.0% | |
| Q2 2019 | -3.5% | -4.3% | -6.1% | |
| Q1 2019 | +3.5% | +2.4% | -4.0% | |
| Q4 2018 | -3.4% | -3.7% | -10.2% | |
| Q3 2018 | +2.5% | +5.9% | -2.1% | |
| Q2 2018 | +0.7% | -1.7% | -5.2% | |
| Q1 2018 | -7.4% | -9.4% | -6.7% | |
| Q4 2017 | +5.6% | +1.2% | +2.2% | |
| Q3 2017 | -3.5% | -6.2% | -9.3% | |
| Q2 2017 | +1.7% | +3.2% | +0.1% | |
| Q1 2017 | -1.3% | -0.5% | -5.1% | |
| Q4 2016 | -7.7% | -8.3% | -5.5% | |
| Q3 2016 | -1.5% | -1.6% | -1.1% | |
| Q2 2016 | -6.4% | -8.2% | -7.0% | |
| Q1 2016 | -12.4% | — | — | |
| Q4 2015 | +2.8% | — | — | |
| Q3 2015 | -0.5% | — | — | |
| Q2 2015 | +4.7% | — | — | |
| Q1 2015 | +2.6% | — | — | |
| Q4 2014 | -7.3% | — | — | |
| Q3 2014 | -1.7% | — | — | |
| Q2 2014 | +1.4% | — | — | |
| Q1 2014 | +3.2% | — | — | |
| Q4 2013 | -0.9% | — | — | |
| Q3 2013 | +5.7% | — | — | |
| Q2 2013 | +4.5% | — | — | |
| Q1 2013 | +10.0% | — | — | |
| Q4 2012 | -0.0% | — | — | |
| Q3 2012 | +3.0% | — | — | |
| Q2 2012 | +8.4% | — | — | |
| Q1 2012 | -0.8% | — | — | |
| Q4 2011 | +1.6% | — | — | |
| Q3 2011 | +0.4% | — | — | |
| Q2 2011 | -1.6% | — | — | |
| Q1 2011 | +0.4% | — | — | |
| Q4 2010 | -1.1% | — | — | |
| Q3 2010 | -1.2% | — | — | |
| Q2 2010 | -0.1% | — | — | |
| Q1 2009 | +2.3% | — | — | |
| Q1 2010 | +0.0% | — | — | |
| Q4 2007 | -0.2% | — | — | |
| Q4 2009 | -0.2% | — | — | |
| Q3 2009 | +5.4% | — | — | |
| Q3 2008 | +5.4% | — | — | |
| Q4 2008 | -5.0% | — | — | |
| Q2 2008 | -5.0% | — | — | |
| Q2 2009 | -5.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro